Experimental
Tesofensine
The prediction game
Call it: rising or fading?
Where does Tesofensine stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: B (good evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5/10
Tesofensine sits in caution because it pairs genuinely strong Phase 2 weight loss with a cardiovascular signal that stalled its own development and a regulatory record that never crossed the finish line. The efficacy is not in question: about 9 to 11 percent at 24 weeks, roughly double the obesity drugs of its era, per Astrup 2008, Lancet. The problem is that the same mechanism raising heart rate is the one driving the weight loss, the pivotal paper carries a journal Expression of Concern, there is no Phase 3 obesity approval, and the follow-up product had to add a beta-blocker to suppress the cardiovascular signal, per Huynh 2022. For routine obesity, an approved GLP-1 does the job with far less risk. The honest read: real weight loss, real cardiovascular and psychiatric cost, and a stalled drug. ✅ Best for: Essentially no one as a self-directed biohack. The only defensible context is a clinician-supervised setting in an approved market, or a monitored orphan-indication program like hypothalamic obesity where the metoprolol-buffered Tesomet form blunted the heart-rate signal, per Huynh 2022, in a patient who has failed or cannot use a GLP-1 drug and will accept close cardiovascular and mood monitoring. Anyone in that narrow window who can source regulated material and track resting heart rate and blood pressure relentlessly. ❌ Avoid if: You have any cardiovascular disease, hypertension, arrhythmia, or elevated resting heart rate, given the chronic tachycardia signal, per Astrup 2008, Lancet. You have any history of anxiety, mood disorder, insomnia, or substance-use disorder, given the monoamine and stimulant-class mechanism. You are pregnant or breastfeeding. You would be sourcing grey-market material of unknown purity. Or you simply want effective, safer weight loss, in which case an FDA-approved GLP-1 like semaglutide is the better-evidenced choice, and even a cautioned stimulant like bromantane sits in a different risk lane.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 6.2%
- BioHarmony Score
- 5/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.